The Oral Antidiabetic Pioglitazone Protects from Neurodegeneration and Amyotrophic Lateral Sclerosis-Like Symptoms in Superoxide Dismutase-G93A Transgenic Mice
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Amyotrophic lateral sclerosis (ALS) represents a fatal neurodegenerative disorder characterized by progressive death of the upper and lower motor neurons. Because accompanying inflammation may interact with and promote neurodegeneration, anti-inflammatory treatment strategies are being evaluated. Because peroxisome proliferator-activated receptor γ (PPARγ) agonists act as potent anti-inflammatory drugs, we tested whether superoxide dismutase (SOD1)-G93A transgenic mice, a mouse model of ALS, benefit from oral treatment with the PPARγ agonist pioglitazone (Pio). Pio-treated transgenic mice revealed improved muscle strength and body weight, exhibited a delayed disease onset, and survived significantly longer than nontreated SOD1-G93A mice. Quantification of motor neurons of the spinal cord at day 90 revealed complete neuroprotection by Pio, whereas nontreated SOD1-G93A mice had lost 30% of motor neurons. This was paralleled by preservation of the median fiber diameter of the quadriceps muscle, indicating not only morphological but also functional protection of motor neurons by Pio. Activated microglia were significantly reduced at sites of neurodegeneration in Pio-treated SOD1-G93A mice, as were the protein levels of cyclooxygenase 2 and inducible nitric oxide synthase. Interestingly, mRNA levels of the suppressor of cytokine signaling 1 and 3 genes were increased by Pio, whereas both the mRNA and protein levels of endogenous mouse SOD1 and of transgenic human SOD1 remained unaffected.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H.-X., et al. (1994) · Science · doi:10.1126/science.8209258 · Cited by 4,143 · cited 15×
“The primary pathological feature of ALS is the loss of motor neurons (Talbot, 2002), which is accompanied by a robust glial response including activation of microglia and astrocytes as well as the expression of cyclooxygenase 2 (COX-2) and nitric oxide synthase (iNOS) in the spinal cord (Phul et al., 2000; Almer et al…”
BackgroundInfluentialThe mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659 · cited 1×
“Peroxisome proliferator-activated receptor ␥ (PPAR␥) ligands were developed as oral antidiabetic drugs after the discovery that PPAR␥ activation increases insulin sensitivity and normalizes serum glucose levels (Berger and Moller, 2002).”
BackgroundYki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Regulation of biosynthesis of nitric oxide.
Nathan, C., & Xie, Q. W. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36703-0 · Cited by 1,669 · cited 1×
“, 1993 ; Nathan and Xie , 1994 ) .”
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Emerging roles of PPARS in inflammation and immunity
Daynes, R. A., & Jones, D. C. (2002) · Nature Reviews Immunology · doi:10.1038/nri912 · Cited by 919 · cited 2×
“Beyond their insulin sensitizing and other metabolic actions, PPAR␥ ligands exert several other PPAR␥-dependent and -independent antineoplastic and anti-inflammatory effects (Daynes and Jones, 2002; Blanquart et al., 2003; Grommes et al., 2004).”
BackgroundIbuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease
Lim, G. P., Yang, F., Chu, T., Chen, P., Beech, W., Teter, B., Tran, T., Ubeda, O., Ashe, K. H., Frautschy, S. A., et al. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-15-05709.2000 · Cited by 884 · cited 2×
“Based on this hypothesis, anti-inflammatory treatment strategies are being developed and tested in animal models and clinical trials of ALS and AD (Lim et al., 2000; In t'Veld et al., 2001; Drachman et al., 2002; Pompl et al., 2003).”
MethodCombs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., & Landreth, G. E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00558.2000 · Cited by 483 · cited 2×
“PPAR␥ ligands suppress microglial activation, thereby protecting neurons from inflammation-mediated cell death (Heneka et al., 1999; Combs et al., 2000).”
BackgroundSelf-citationCis3/Socs3/Ssi3 Plays a Negative Regulatory Role in Stat3 Activation and Intestinal Inflammation
Suzuki, A., Hanada, T., Mitsuyama, K., Yoshida, T., Kamizono, S., Hoshino, T., Kubo, M., Yamashita, A., Okabe, M., Takeda, K., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.4.471 · Cited by 471
Inflammatory processes in amyotrophic lateral sclerosis
McGeer, P. L., & McGeer, E. G. (2002) · Muscle & Nerve · doi:10.1002/mus.10191 · Cited by 470 · cited 2×
“More recently, an inflammatory component of the disease has been described (McGeer and McGeer, 2002), and potentially detrimental mediators and systems of inflammation were discovered at sites of degenerating motor neurons (Weydt et al.”
BackgroundAntineoplastic effects of peroxisome proliferatoractivated receptor γ agonists
Grommes, C., Landreth, G. E., & Heneka, M. T. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01509-8 · Cited by 440 · cited 1×
“Beyond their insulin sensitizing and other metabolic actions, PPAR ligands exert several other PPAR -dependent and -independent antineoplastic and anti-inflammatory effects (Daynes and Jones, 2002; Blanquart et al., 2003; Grommes et al., 2004).”
BackgroundSelf-citationCyclooxygenase-2: Molecular Biology, Pharmacology, and Neurobiology
O'Banion, M. K. (1999) · Critical Reviews in Neurobiology · doi:10.1615/critrevneurobiol.v13.i1.30 · Cited by 404 · cited 1×
“Coinduction of both enzymes by several factors including glutamate release and secretion of proinflammatory cytokines may be caused by similar or identical stimulators (O’Banion, 1999), because the COX-2 and iNOS promoters share several binding sites for signal transduction factors involved in inflammatory signal casc…”
BackgroundWatson, G. S., & Craft, S. (2003) · CNS Drugs · doi:10.2165/00023210-200317010-00003 · Cited by 397
Shouda, T., Yoshida, T., Hanada, T., Wakioka, T., Oishi, M., Miyoshi, K., Komiya, S., Kosai, K.-I., Hanakawa, Y., Hashimoto, K., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13568 · Cited by 395
Breidert, T., Callebert, J., Heneka, M. T., Landreth, G., Launay, J. M., & Hirsch, E. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00990.x · Cited by 373 · cited 1×
“, 2003), Parkinson’s disease (Breidert et al., 2002), and stroke (Sundararajan et al.”
BackgroundSelf-citationA role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis
Barbeito, L. H., Pehar, M., Cassina, P., Vargas, M. R., Peluffo, H., Viera, L., Estévez, A. G., & Beckman, J. S. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.05.003 · Cited by 327 · cited 2×
“…2002), which is accompanied by a robust glial response including activation of microglia and astrocytes as well as the expression of cyclooxygenase 2 (COX-2) and nitric oxide synthase (iNOS) in the spinal cord (Phul et al., 2000; Almer et al., 2001; Yasojima et al., 2001; Barbeito et al., 2004).”
BackgroundBlanquart, C., Barbier, O., Fruchart, J. C., Staels, B., & Glineur, C. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00214-0 · Cited by 312 · cited 2×
“Beyond their insulin sensitizing and other metabolic actions, PPAR␥ ligands exert several other PPAR␥-dependent and -independent antineoplastic and anti-inflammatory effects (Daynes and Jones, 2002; Blanquart et al., 2003; Grommes et al., 2004).”
BackgroundDrachman, D. B., Frank, K., Dykes‐Hoberg, M., Teismann, P., Almer, G., Przedborski, S., & Rothstein, J. D. (2002) · Annals of Neurology · doi:10.1002/ana.10374 · Cited by 307 · cited 2×
“The hypothesis that neuroinflammation , once it has been initi - ated by degenerating neurons , significantly contributes to the progression of motor neuron death in ALS has been supported by studies on SOD1 transgenic mice reporting protective effects of cyclooxygenase inhibitors ( Drachman et al .”
MethodInteraction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia
Nogawa, S., Forster, C., Zhang, F., Nagayama, M., Ross, M. E., & Iadecola, C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10966 · Cited by 295 · cited 1×
“Thus, NO may increase the catalytic activity of COX-2, thereby increasing the production of proinflammatory prostanoids (Nogawa et al., 1998).”
BackgroundFeinstein, D. L., Galea, E., Gavrilyuk, V., Brosnan, C. F., Whitacre, C. C., Dumitrescu‐Ozimek, L., Landreth, G. E., Pershadsingh, H. A., Weinberg, G., & Heneka, M. T. (2002) · Annals of Neurology · doi:10.1002/ana.10206 · Cited by 294 · cited 2×
“…for total RNA and protein, and both mouse and human SOD1 expression levels were determined findings in animal models of multiple sclerosis (Niino et al., 2001; Feinstein et al., 2002; Natarajan et al., 2003), Parkinson’s disease (Breidert et al., 2002), and stroke (Sundararajan et al., 2005).”
BackgroundResultSelf-citationYoshihara, T., Ishigaki, S., Yamamoto, M., Liang, Y., Jun, Niwa, I., Takeuchi, H., Doyu, M., & Sobue, G. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2001.00683.x · Cited by 275 · cited 2×
“…, motor neuron loss and neuroinflammation, can be found in transgenic mice overexpressing mutant variants of the human gene encoding for copper/zinc superoxide dismutase (SOD1), which have been linked to inherited ALS (Gurney et al., 1994; Hensley et al., 2002; Yoshihara et al., 2002; Kunst, 2004).”
BackgroundHeneka, M. T., Klockgether, T., & Feinstein, D. L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-18-06862.2000 · Cited by 269 · cited 1×
“We have demonstrated that PPAR agonists reduce amyloid peptide and cytokine mediated neuroinflammation and neurotoxicity in vitro (Heneka et al., 1999; Combs et al., 2000) and in vivo (Heneka et al., 2000).”
BackgroundSelf-citationSundararajan, S., Gamboa, J. L., Victor, N. A., Wanderi, E. W., Lust, W. D., & Landreth, G. E. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2004.10.021 · Cited by 266 · cited 1×
“, 2002), and stroke (Sundararajan et al., 2005).”
Self-citationShiomi, T., Tsutsui, H., Hayashidani, S., Suematsu, N., Ikeuchi, M., Wen, J., Ishibashi, M., Kubota, T., Egashira, K., & Takeshita, A. (2002) · Circulation · doi:10.1161/01.cir.0000039346.31538.2c · Cited by 255
Almer, G., Vukosavic, S., Romero, N., & Przedborski, S. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0722415.x · Cited by 231
Assessing disease onset and progression in the SOD1 mouse model of ALS
Weydt, P., Hong, S. Y., Kliot, M., & Möller, T. (2003) · NeuroReport · doi:10.1097/00001756-200305230-00029 · Cited by 227
Shimazu, T., Inoue, I., Araki, N., Asano, Y., Sawada, M., Furuya, D., Nagoya, H., & Greenberg, J. H. (2005) · Stroke · doi:10.1161/01.str.0000152271.21943.a2 · Cited by 218
Park, E. J., Park, S. Y., Joe, E.-H., & Jou, I. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210819200 · Cited by 214 · cited 1×
“Interestingly, SOCS-1 and SOCS-3 have been reported to increase in response to TZDs in microglia and astrocytes in vitro, which in turn inhibit Janus kinase–signal transducer and activator of transcription (JAKSTAT) inflammatory signal transduction (Park et al., 2003).”
BackgroundHensley, K., Floyd, R. A., Gordon, B., Mou, S., Pye, Q. N., Stewart, C., West, M., & Williamson, K. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00968.x · Cited by 198
Niino, M., Iwabuchi, K., Kikuchi, S., Ato, M., Morohashi, T., Ogata, A., Tashiro, K., & Onoé, K. (2001) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(01)00285-5 · Cited by 188
Brooke, M. H., & Engel, W. K. (1969) · Neurology · doi:10.1212/wnl.19.4.378 · Cited by 175
Landreth, G. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00296-2 · Cited by 169 · cited 3×
“Originally developed as oral antidiabetics , agonists of PPAR␥ have been found to exert potent anti-inflammatory effects in several models of neuroinflammation (Landreth and Heneka, 2001; Feinstein, 2003).”
BackgroundSelf-citationHeneka, M. T., L. Feinstein, D., Galea, E., Gleichmann, M., Wüllner, U., & Klockgether, T. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00192-7 · Cited by 150 · cited 2×
“PPAR␥ ligands suppress microglial activation, thereby protecting neurons from inflammation-mediated cell death (Heneka et al., 1999; Combs et al., 2000).”
BackgroundSelf-citationMarked increase in cyclooxygenase-2 in ALS spinal cord: Implications for therapy
Yasojima, K., Tourtellotte, W. W., McGeer, E. G., & McGeer, P. L. (2001) · Neurology · doi:10.1212/wnl.57.6.952 · Cited by 148
Talbot, K. (2002) · Postgraduate Medical Journal · doi:10.1136/pmj.78.923.513 · Cited by 147
Pompl, P. N., Ho, L., Bianchi, M., McManus, T., Qin, W., & Pasinetti, G. M. (2003) · The FASEB Journal · doi:10.1096/fj.02-0876fje · Cited by 144 · cited 2×
“, 2002 ; Pompl et al .”
Method(1997) · PubMed · Cited by 139
Complex Genetics of Amyotrophic Lateral Sclerosis
Kunst, C. B. (2004) · The American Journal of Human Genetics · doi:10.1086/426001 · Cited by 115
Feinstein, D. L. (2003) · Diabetes Technology & Therapeutics · doi:10.1089/152091503763816481 · Cited by 115
Bright, J. J., Natarajan, C., Muthian, G., Barak, Y., & Evans, R. M. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.5743 · Cited by 103 · cited 1×
“Our results strongly suggest that Pio-mediated suppression of inflammation may offer a new therapeutic avenue in ALS treatment, as supported by previous findings in animal models of multiple sclerosis (Niino et al., 2001; Feinstein et al., 2002; Natarajan et al., 2003), Parkinson’s disease (Breidert et al.”
ResultAnalysis of the cellular expression pattern of β‐CGRP in α‐CGRP‐deficient mice
Schütz, B., Mauer, D., Salmon, A., Changeux, J., & Zimmer, A. (2004) · The Journal of Comparative Neurology · doi:10.1002/cne.20211 · Cited by 63
Self-citationSasaki, S., Warita, H., Abe, K., & Iwata, M. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.9.839 · Cited by 46 · cited 1×
“Coinduction of COX-2 and iNOS were described in several neurodegenerative disorders including ALS, as well as in the SOD1-G93A model used in this study (Almer et al., 1999, 2001; Sasaki et al., 2001).”
MethodNeuro-inflammation as a therapeutic target in amyotrophic lateral sclerosis.
Weydt, P., Weiss, M. D., Möller, T., & Carter, G. T. (2002) · PubMed · Cited by 38
Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance.
Patsouris, D., Müller, M. M., & Kersten, S. (2004) · PubMed · Cited by 33
Effects of intraperitoneal injection of Rofecoxib in a mouse model of ALS
Azari, M. F., Profyris, C., Grande, M. R. L., Lopes, E. C., Hirst, J. J., Petratos, S., & Cheema, S. S. (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2004.00987.x · Cited by 29 · cited 1×
“, 2003 ; Azari et al .”
Expression of nitric oxide synthase isoforms in spinal cord in amyotrophic lateral sclerosis
Phul, R. K., Shaw, P. J., Ince, P. G., & Smith, M. E. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/14660820050515089 · Cited by 27 · cited 2×
“…2002), which is accompanied by a robust glial response including activation of microglia and astrocytes as well as the expression of cyclooxygenase 2 (COX-2) and nitric oxide synthase (iNOS) in the spinal cord (Phul et al., 2000; Almer et al., 2001; Yasojima et al., 2001; Barbeito et al., 2004).”
BackgroundActivate your online subscription
(2001) · Neurology · doi:10.1212/wnl.56.8.1079 · Cited by 12
Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease.
van Geel (2001) · Open Repository and Bibliography (University of Luxembourg) · doi:10.1002/1531-8249(20010201)49:2 · Cited by 7 · cited 2×
“…2002), which is accompanied by a robust glial response including activation of microglia and astrocytes as well as the expression of cyclooxygenase 2 (COX-2) and nitric oxide synthase (iNOS) in the spinal cord (Phul et al., 2000; Almer et al., 2001; Yasojima et al., 2001; Barbeito et al., 2004).”
BackgroundMethod
Cited by
Innate immune activation in neurodegenerative disease
Heneka, M. T., Kummer, M. P., & Latz, E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3705 · Cited by 1,437
Self-citationTransvascular delivery of small interfering RNA to the central nervous system
Kumar, P., Wu, H., McBride, J. L., Jung, K.-E., Hee Kim, M., Davidson, B. L., Kyung Lee, S., Shankar, P., & Manjunath, N. (2007) · Nature · doi:10.1038/nature05901 · Cited by 1,246
Macrophage activation and its role in repair and pathology after spinal cord injury
Gensel, J. C., & Zhang, B. (2015) · Brain Research · doi:10.1016/j.brainres.2014.12.045 · Cited by 771
The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies
Maalouf, M., Rho, J. M., & Mattson, M. P. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.09.002 · Cited by 574
Alzheimer's disease as homeostatic responses to age-related myelin breakdown
Bartzokis, G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.08.007 · Cited by 546
Metadata
- Authors
- Schütz, B., Reimann, J., Dumitrescu-Ozimek, L., Kappes-Horn, K., Landreth, G. E., Schürmann, B., Zimmer, A., & Heneka, M. T.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2005-08-24
- Volume
- 25
- Issue
- 34
- Pages
- 7805-7812
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2163791529
- Cited by
- 225
- References
- 50
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.